PrEP review clinic outcomes and renal PrEP outcomes
| Reason for referral to PrEP review clinic | |
| Reason for referral | Unique PrEP users, n (%) |
| Renal | 114 (51.8) |
| Abnormal eGFR and/or high creatinine | 89 (40.5) |
| Proteinuria (>30 mg/mmol and/or ≥1+ protein on urine dipstick) | 15 (6.8) |
| Other renal issues not presenting with abnormal eGFR or proteinuria | 10 (4.5) |
| Side effects | 59 (26.8)* |
| Comorbidities | 38 (17.2) |
| Concerns about safety of PrEP | 15 (6.8) |
| Drug–drug interactions | 8 (3.6) |
| Hepatitis B | 8 (3.6) |
| Bone health | 7 (3.2) |
| Other | 9 (4.1) |
| Renal eGFR cases: possible cause and management following consultation (n=89) | |||||
| Referral eGFR (mL/min/1.73 m2) | Protein supplements: to stop these and retest | Alternative explanation, already being monitored | Alternative explanation, no extra monitoring needed | No explanation, further investigated or monitored | Total (n=89) |
| ≥90 (had abnormal eGFR or raised creatinine and normalised on repeat) | 2 | 2 | 0 | 1 | 5 |
| 60–89 | 13 | 17 | 4 | 5 | 39 |
| 45–59 | 18 | 8 | 1 | 8 | 35 |
| 30–44 | 3 | 6 | 0 | 1 | 10 |
*Out of 59 PrEP users, 47 (76.7%) obtained PrEP on at least one other occasion following their initial PrEP review clinic appointment, 9 (15.3%) had unknown outcomes and 3 (5.1%) have not restarted PrEP due to reasons including an allergic reaction with bullous lesions which recurred on rechallenge and led to discontinuation of PrEP. The regimen for increasing tolerance is provided in online supplemental table 4.
†
eGFR, estimated glomerular filtration rate; PrEP, pre-exposure prophylaxis.